ST. PETERSBURG, Fla., Feb. 21, 2013 /PRNewswire/ -- Premier Biomedical, Inc. (OTC-BB: BIEI) today announced that it has acquired exclusive rights to a provisional patent application against Retinitis Pigmentosa. This exclusive intellectual property right, a result of Premier's long-standing licensing agreements, proposes a novel method for treating the degenerative eye disease via the targeted removal of specified target antigens. This is the latest of many proposed applications of Premier Biomedical, Inc.'s Felder Doctrine.
Retinitis Pigmentosa (RP) is a group of inherited disorders characterized by a peripheral vision loss that can eventually lead to central vision loss. An estimated 100,000 people in the United States have RP, mainly caused by gene mutations inherited from one or both parents. RP is most commonly found in isolation, but it can be associated with systemic disease. The most common systemic association is hearing loss, which occurs in up to 30% of patients. There is a great continuing need for treatments for RP.
"We are very excited to make what could be a first step towards a truly effective treatment against a disease which has blinded many thousands of patients" said Dr. Mitchell S. Felder, inventor of the technology and Chairman of Premier Biomedical, Inc.'s Scientific Advisory Board, "As with our other proposed therapies, the proposed therapy against Retinitis Pigmentosa described in the new provisional patent application focuses on physically removing those molecular compounds responsible for the disease."
Premier's development against Retinitis Pigmentosa follows a number of significant advances in treatment against Cancerthe most significant of which has been the extraction of molecular compounds involved in tumor development and metastasis within ten minutes, preceding the subsequent death of targeted cancer tissue within 24 hours. Significantly, it is believed that this methodology would lack side effects associated with conventional treatments. Additionally, in targeting Cancer, Premier researchers have successfully removed a specified inflammatory cytokine at a picogram level (one trillionth of a gram).
Beyond its research development programs targeting Cancer, Premier has proposed a treatment protocol for the currently incurable neurologic condition Neurofibromatosis and has also successfully removed the majority of target antigens associated with Clinical Depression and Suicidal Ideation from a heterogeneous mixture.
About Premier Biomedical, Inc.
Premier Biomedical, Inc. is a research-based company that intends to discover and develop medical treatments for humans, specifically targeting the treatment of Alzheimer's Disease, Fibromyalgia, Multiple Sclerosis, Traumatic Brain Injury, Amyotrophic Lateral Sclerosis (ALS/Lou Gehrig's Disease), Blood Sepsis and Viremia, and Cancer. Premier has licensed the technology behind multiple provisional patents in the United States and a PCT Europe National Patent in the areas of Cancer, Sepsis, and Multiple Sclerosis. Founded in 2010, Premier is headquartered in Florida, with offices in Pennsylvania. The Company's common stock trades on the fully reporting Over-The-Counter Bulletin Board under the ticker symbol "BIEI." www.premierbiomedicalinc.com
Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Premier Biomedical, Inc. cautions that statements made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time statements are made. These statements may address issues that involve significant risks, uncertainties, estimates and assumptions made by management. Actual results could differ materially from current projections or implied results. Premier Biomedical, Inc. undertakes no obligation to revise these statements following the date of this news release.
Premier Biomedical, Inc.
William A. Hartman, CEO
SOURCE Premier Biomedical, Inc.